What Capita3 does

Capita3 is a women-led venture capital firm headquartered in Minneapolis, MN, that invests in early-stage and growth-stage companies transforming health and healthcare at the intersection of personalization, prediction, and precision technologies. The firm was founded around 2016 and is led by Co-Founder and Managing Director Pamela York, Managing Partner Kathy Tune, and Partner Sara Russick, supported by an associate and an advisory board of at least ten industry operators and investors. Capita3 reports $400M in assets under management deployed across five funds, with 100 deals completed, 5 unicorns identified, and over $1B in generated returns; its portfolio spans digital health, femtech, neurotech, microbiome therapeutics, and obesity care, with notable positions in b.well Connected Health, Claros Technologies, NextSense, Flourish Care, MDisrupt, FlyteHealth, Gabbi, Joylux, Marani Health, Carallel, Persephone Biosciences, and Paterna.

Capita3's core product is its investment and leadership platform, which combines capital deployment with the Leader Launch corporate-partnered leadership program designed to give scientists and founders the playbook and support to scale healthcare companies. The firm generates revenue through traditional venture capital economics: management fees on committed and invested AUM and carried interest on realized gains from exits such as the EmpowerU sale to FullBloom in 2023. Deal flow is sourced through direct founder relationships, the Leader Launch corporate partner network, and ecosystem partnerships including a 2024 venture capital partnership with Medical Alley. Distribution and brand-building occur via newsletter, LinkedIn, industry conferences (HLTH, RAISE Global Summit, Recast Capital), and earned media around portfolio milestones.

The firm's positioning as a healthcare-specialist, women-led fund is reinforced by external recognition including the 2024 American Entrepreneurship Top Women-Led Fund designation, the Recast Capital 2023 inaugural Accelerate Program cohort selection, and Kathy Tune's 2025 Top 25 in '25 — Women in Technology Investing Kayo Conference Series honor. While Capita3 is a small team (roughly four core members plus advisors) and does not disclose firm-level financials, its disclosed portfolio momentum — including b.well's 2026 selection as OpenAI's exclusive ChatGPT health partner and multiple 2024–2025 portfolio financings — indicates an active deployment cycle and a developing track record of category-defining healthcare bets.

Name

Capita3

Legal name

Capita3

Website

https://capita3.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

1–10 employees

Short description

Capita3 is a women-led, Minneapolis-based venture capital firm that manages $400M across five healthcare-focused funds, investing early in companies transforming health at the intersection of personalization, prediction, and precision technologies.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Other Investment Pools and Funds (5259)

SIC

Investment Advice (6282)

akta.pro primary industry

Micro-VC & Angel Funds (FSANAAAI)

Keywords

• Venture capital funds
• Healthcare investments
• Digital health investing
• Early stage funding
• Fund management services

Headquarters

HQ city

Minneapolis

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Fund Management: Capita3 generates returns through venture capital fund management, investing in early-stage and growth-stage healthcare companies. The firm has achieved $1B+ in returns across 5 funds with $400M AUM, completing 100 deals and identifying 5 unicorns.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Capita3 is an early-stage venture capital firm that manages healthcare-focused investment funds (Funds I, II, and IIA) with $400M AUM, deploying capital into digital health and deep tech companies at the intersection of personalization, prediction, and precision. The firm supplements capital with strategic support and runs the Leader Launch™ leadership platform, in partnership with top corporates, to give scientists and founders the playbook and support needed to scale healthcare ideas and companies.

Product overview

Capita3 is a venture capital firm, not a product company. It does not offer its own products or services. Capita3 is an investment firm that manages funds focused on healthcare and wellness technology companies, providing capital and support to portfolio companies including b.well Connected Health, Claros Technologies, Flourish Care, NextSense, Persephone Biosciences, Carallel, FlyteHealth, Gabbi, JoyLux, Marani Health, MDisrupt, Paterna, and others.

Differentiator

Problem solved

Functional benefit

Brands

• Leader Launch: Leadership platform program partnered with top corporates to give scientists and founders the playbook and support to scale their healthcare ideas and companies

Products and services

• Venture Capital Funds (Funds I, II, and IIA) Capita3 manages five venture capital funds (Funds I, II, and IIA) that deploy capital into early-stage and growth-stage healthcare technology companies at the intersection of personalization, prediction, and precision. Limited partners commit capital to these funds in exchange for management fees and a share of carried interest on returns.
• Leader Launch™ Leadership Platform Leader Launch™ is Capita3's leadership development platform, partnered with top corporates, that gives scientists and founders the playbook and support to scale their healthcare ideas and companies. The platform creates next-generation leaders for next-generation healthcare.

Quantifiable outcome

• $1B+ in returns generated
• +3 more outcomes

Named customers13 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

30 partnerships are on record, tiered core.

• myTomorrows/b.wellcoreStrategic or Co-development Partner · 26 May 2026Capita3 portfolio company b.well partnered with myTomorrows to transform clinical trial access for patients.
• Humana, Noom, Welldoc/b.wellcoreStrategic or Co-development Partner · 10 April 2026Capita3 portfolio company b.well partnered with Humana, Noom, and Welldoc to expand health data access as part of CMS push.
• Perplexity/b.wellcoreStrategic or Co-development Partner · 20 March 2026Capita3 portfolio company b.well partnered with Perplexity to bring trusted health data to AI search, enabling personalized health answers.
• Samsung/b.wellcoreStrategic or Co-development Partner · 11 March 2026Capita3 portfolio company b.well partnered with Samsung to turn smartphones into the front door of healthcare through the 'Kill the Clipboard' initiative.
• athenahealth/b.wellcoreStrategic or Co-development Partner · 10 February 2026Capita3 portfolio company b.well partnered with athenahealth to introduce patient-controlled digital health data sharing at the point of care.
• OpenAI/b.wellcoreStrategic or Co-development Partner · 8 January 2026Capita3 portfolio company b.well was selected by OpenAI as the exclusive ChatGPT health partner, powering health data connectivity for 800M+ ChatGPT users.
• FlyteHealth/U.S. MedicarecoreStrategic or Co-development Partner · 15 December 2025Capita3 portfolio company FlyteHealth was featured for U.S. Medicare ACCESS Program, marking a major step forward in scalable cardio-kidney-metabolic care.
• Peptonic/JoyluxcoreChannel Partner/ Reseller/ Distributor · 23 November 2025Capita3 portfolio company Joylux signed strategic distribution agreement with Peptonic for USA, Canada, Mexico, and the UK.
• Google/b.wellcoreStrategic or Co-development Partner · 20 October 2025Capita3 portfolio company b.well was selected by Google to unlock the potential of personalized health.
• FlyteHealth/Heartbeat HealthcoreStrategic or Co-development Partner · 23 September 2025Capita3 portfolio company FlyteHealth collaborated with Heartbeat Health to deliver integrated cardiometabolic and cardiovascular care.
• Independence Blue Cross/CarallelcoreStrategic or Co-development Partner · 14 September 2025Independence Blue Cross Post-Acute Care Program with Carallel improves outcomes, lowers costs, and earned national BCBSA award.
• Persephone Biosciences/Kroger HealthcoreStrategic or Co-development Partner · 9 September 2025Capita3 portfolio company Persephone Biosciences announced topline results from AMBROSIA Food as Medicine Study with Kroger Health.
• AmeriHealth Caritas/CarallelcoreStrategic or Co-development Partner · 28 July 2025Capita3 portfolio company Carallel strengthened support for family caregivers through partnership with AmeriHealth Caritas.
• Marani Health/Wyoming PayorcoreStrategic or Co-development Partner · 26 July 2025Capita3 portfolio company Marani Health partnered with leading Wyoming payor to expand 24/7 remote pregnancy monitoring access.
• Wellstar/GabbicoreStrategic or Co-development Partner · 11 June 2025Capita3 portfolio company Gabbi partnered with Wellstar to assess women's future risk of breast cancer.
• Myriad Genetics/GabbicoreStrategic or Co-development Partner · 11 June 2025Capita3 portfolio company Gabbi partnered with Myriad Genetics to increase access to hereditary cancer risk assessment tools.
• Independence Blue Cross/CarallelcoreStrategic or Co-development Partner · 16 April 2025Capita3 portfolio company Carallel expanded access to Independence Blue Cross Medicare Advantage members and their caregivers.
• Ouma Health/Marani HealthcoreStrategic or Co-development Partner · 5 January 2025Capita3 portfolio companies Ouma Health and Marani Health partnered for maternity care in underserved areas.
• Muse Health/FlyteHealthcoreStrategic or Co-development Partner · 31 October 2024Capita3 portfolio company FlyteHealth partnered with Muse Health to increase access to medical obesity care.
• MDisrupt/American Heart AssociationcoreStrategic or Co-development Partner · 17 October 2024Capita3 portfolio company MDisrupt secured American Heart Association partnership with AHA Ventures investment and strategic collaboration for association members.
• Halle Berry's Respin/JoyluxcoreStrategic or Co-development Partner · 24 September 2024Capita3 portfolio company Joylux announced strategic partnership with Halle Berry's Respin to advance intimate health and wellness.
• Zerigo Health/NextivacoreStrategic or Co-development Partner · 11 June 2024Capita3 portfolio company Zerigo Health partnered with Nextiva to expand benefits for employees with chronic skin conditions.
• Marani Health/AWScoreStrategic or Co-development Partner · 17 May 2024Capita3 portfolio company Marani Health was selected to participate in Amazon Web Services $40 million Health Equity Program.
• Medical AlleycoreStrategic or Co-development Partner · 15 May 2024Medical Alley announced a venture capital partnership with Capita3 to accelerate innovation and investment within its global investor and corporate partner network.
• AWS/b.wellcoreStrategic or Co-development Partner · 9 April 2024Capita3 portfolio company b.well joined the AWS Partner Network and became available in AWS Marketplace to accelerate growth of healthcare ecosystems.
• MDisrupt/California Health Care FoundationcoreStrategic or Co-development Partner · 8 January 2024Capita3 portfolio company MDisrupt partnered with California Health Care Foundation to fuel digital health pioneers revolutionizing healthcare for all.
• CLEAR/b.wellcoreStrategic or Co-development Partner · 10 October 2023Capita3 portfolio company b.well partnered with CLEAR to target 'portal-itis' with strategic partnership.
• Samsung Health/b.wellcoreStrategic or Co-development Partner · 9 October 2023Samsung Health tapped Capita3 portfolio company b.well to make personalized healthcare a reality, integration unveiled at HLTH 2023.
• EmpowerU/FullBloomcoreStrategic or Co-development Partner · 27 September 2023Capita3 announced acquisition of portfolio company EmpowerU by FullBloom, helping young people thrive in academics and life.
• Corporate Partners (Leader Launch)coreStrategic or Co-development PartnerCapita3 has partnered with top corporates to deliver their Leader Launch platform program, which gives scientists and founders the playbook and support to scale their healthcare ideas and companies.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Rock Health: Rock Health is a direct peer — an early-stage digital health venture fund with a similar thesis around healthcare innovation and a comparable seed-stage investing focus. Both firms target the intersection of technology and healthcare transformation.
• Define Ventures: Define Ventures is a direct peer — a healthcare-focused early-stage VC led by a woman founder (Lynne Chou O'Keefe), with a similar operating-platform-plus-capital model and seed-stage healthcare mandate. Directly comparable in fund size, sector focus, and leadership positioning.
• Flare Capital Partners: Flare Capital Partners is a direct peer — an early-stage healthcare technology VC investing across digital health, health IT, and care delivery. Closely comparable in fund size, stage focus, and healthcare-only thesis.
• 7wireVentures: 7wireVentures is a direct peer — an early-stage digital health-focused VC with an operating platform model (Connected Consumer Health). Similar thesis on consumer-driven, technology-enabled healthcare transformation.
• .406 Ventures: .406 Ventures is a direct peer — an early-stage healthcare and technology VC investing primarily at seed and Series A in digital health, with comparable fund size and stage focus.
• SteelSky Ventures: SteelSky Ventures is a direct peer — a female-founded VC focused on women's health and digital health. Comparable in women-led positioning, healthcare specialization, and seed-stage approach.

Broad incumbents

• Andreessen Horowitz (a16z Bio/Health): a16z is a broad incumbent — a large, multi-stage VC with a dedicated Bio/Health fund. Comparable in healthcare investment thesis but materially larger in AUM, check size, and stage coverage.
• GV (Google Ventures): GV is a broad incumbent — a large generalist VC that invests heavily in healthcare and life sciences. Comparable in digital health deal flow but materially larger in AUM and stage flexibility.
• General Catalyst: General Catalyst is a broad incumbent — a multi-stage VC with a deep health-focused practice (Health Assurance). Overlaps with Capita3 in digital health and care delivery themes but at materially larger scale and later stages.

Others

• Recast Capital: Recast Capital is an ecosystem peer — an allocator and accelerator program for emerging VC managers (selected Capita3 for its 2023 inaugural Accelerate cohort). Comparable in mission to broaden VC access but operates as an LP/incubator rather than a direct investor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments7 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Capita3